Non-Small Cell Lung Cancer - Metastatic

1st line

Squamous

IRB# 18114 BrightPath
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects with PD-L1+ Non-Small Cell Lung Cancer

IRB# 19009
A Phase IIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Non-squamous

IRB# 19114 BrightPath
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects with PD-L1+ Non-Small Cell Lung Cancer

IRB# 19009
A Phase IIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

IRB# 19009
A Phase IIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

IRB# 11462 A Randomized, Open-label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib (AZD6244) plus Paclitaxel as Second-Line Treatment for Stage IIIB or IV NSCLC

IRB# 18114 BrightPath
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects with PD-L1+ Non-Small Cell Lung Cancer

IRB# 11046 Lung-MAP: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

2nd/3rd Line

BrightPath
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects with PD-L1+ Non-Small Cell Lung Cancer

http://www.ohsu.edu/research/rda/so/knight.php